SIMPONI (golimumab)

Key points

Favourable opinion for maintenance of reimbursement in the treatment of:

• moderate to severe, active rheumatoid arthritis in adults, only in combination with methotrexate (MTX), when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate
• active and progressive psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate
• severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy
• severe, active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).